Business Context and Reporting Period
This Form 8-K, dated November 8, 2022, reports on ReShape Lifesciences Inc. (RSLS), a Delaware corporation. The filing details a material definitive agreement entered into on November 8, 2022, and closed on November 9, 2022, involving a registered direct offering and a concurrent private placement to an institutional investor.
Key Financial Metrics and Transaction Details
The transaction generated aggregate gross proceeds of $750,000 before deducting placement agent fees and offering expenses. The capital raise consisted of the following components:
- Common Stock: 2,392,524 shares sold at $0.26 per share.
- Series D Mirroring Preferred Stock: 2,500 shares sold at $0.001 per share.
- Pre-funded Warrants: Warrants to purchase 492,091 shares sold at $0.259 per share.
- Common Warrants: Warrants to purchase 2,884,615 shares issued in a concurrent private placement.
Placement Agent Fees: Maxim Group LLC received a cash fee equal to 7.0% of gross proceeds, expense reimbursement, and warrants to purchase 144,230 shares (5.0% of the aggregate common stock and equivalents).
Material Changes and Agreements
The filing discloses several material changes to the company's capital structure and existing securities:
- Warrant Amendment: Existing warrants held by the investor to purchase 5,348,106 shares were amended. The exercise price was reduced from $0.6665 to $0.30 per share. The expiration date for warrants expiring in June 2026 was extended by 5.5 years. These amended warrants are not exercisable for six months following the closing.
- Reverse Stock Split Proposal: The company plans to call an annual meeting to approve a reverse stock split (ratio to be determined) and increase authorized common stock from 100 million to 300 million shares.
- Voting Rights: The Series D Preferred Stock carries no dividends and is not convertible. However, each share grants 30,000 votes on the reverse stock split and charter amendment proposals. The investor agreed to vote these shares in favor of the proposals.
Outlook, Risks, and Contingencies
Future Actions: The Series D Preferred Stock will automatically terminate following stockholder approval of the reverse stock split. The Common Warrants have an exercise price of $0.30, are exercisable six months after issuance, and expire five years after the initial exercise date.
Risks and Restrictions: The Common Warrants are subject to a 4.99% beneficial ownership limitation. The securities were offered to an accredited investor under Section 4(a)(2) and Rule 506(b) exemptions and are not registered under the Securities Act of 1933.
Investor Verification Checklist
- Verify the final ratio and implementation date of the proposed reverse stock split.
- Confirm the net proceeds received after deducting the 7.0% placement fee and offering expenses.
- Monitor the status of the annual stockholder meeting required to approve the charter amendments and reverse split.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for additional covenants or restrictions.
- Check subsequent filings for the actual exercise of the new and amended warrants.